ArticleProceedings of the National Academy of Sciences of the United States of America2022
Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed.
- ASD: antigen-specific antibody database.mAbs · 2026Article
- The Evolution of Artificial Intelligence in Antibody Design: From Structure-Based Engineering to Generative Models.Antibodies (Basel, Switzerland) · 2026Review
- PythiaStudio: a one-stop protein engineering platform powered by Pythia model suite.Nucleic acids research · 2026Article
- USP-ddG: a unified structural paradigm with data efficacy and mixture-of-experts for predicting mutational effects on protein-protein interactions.Bioinformatics (Oxford, England) · 2026Article
- Update and reuse: Structure-guided nanobody evolution against SARS-CoV-2 escape.PLoS pathogens · 2026Article
- AI-Driven BCR Modeling for Precision Immunology.International journal of molecular sciences · 2026Review
- Antibody-antigen neutralization prediction by integrating structural information distillation and physicochemical constraints.Briefings in bioinformatics · 2026Article
- Contrastive learning enables epitope overlap predictions for targeted antibody discovery.Patterns (New York, N.Y.) · 2026Article
- GeoGAD: geometry-aware antibody design framework for complementarity-determining region precision engineering.Bioinformatics (Oxford, England) · 2026Article
- Harnessing deep learning to accelerate the development of antibodies and aptamers.Acta pharmaceutica Sinica. B · 2026Review
- HERMES: Holographic Equivariant neuRal network model for Mutational Effect and Stability prediction.bioRxiv : the preprint server for biology · 2026Article
- Artificial intelligence directed computational protein design: lessons from COVID-19 for pandemic-ready vaccines and antibody therapeutics.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026Review
- Generalizable and scalable protein stability prediction with rewired protein generative models.Nature communications · 2025Article
- Explore antibody repertoire in the era of AI.Acta biochimica et biophysica Sinica · 2025Article
- Optimizing the breadth of SARS-CoV-2-neutralizing antibodies in vivo and in silico.Human vaccines & immunotherapeutics · 2025Review
- Artificial intelligence-driven anticancer peptide discovery.iMetaOmics · 2025Review
- Article
- High-accuracy protein complex structure modeling based on sequence-derived structure complementarity.Nature communications · 2025Article
- PPAC: Predicting Protein-Protein Affinity Changes Induced by Amino Acid Mutations Using Protein Large Language Models.ACS omega · 2025Article
- A synergistic generative-ranking framework for tailored design of therapeutic single-domain antibodies.Cell discovery · 2025Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SignificanceSARS-CoV-2 continues to evolve through emerging variants, more frequently observed with higher transmissibility. Despite the wide application of vaccines and antibodies, the selection pressure on the Spike protein may lead to further evolution of variants that include mutations that can evade immune response. To catch up with the virus's evolution, we introduced a deep learning approach to redesign the complementarity-determining regions (CDRs) to target multiple virus variants and obtained an antibody that broadly neutralizes SARS-CoV-2 variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.